Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05720819 · ClinicalTrials.gov registry record · NA

Biofeedback-VR for Treatment of Chronic Migraine

A NA study of Virtual Reality and Chronic Migraine, sponsored by University of Washington.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05720819: Completed NA study of Virtual Reality and Chronic Migraine, sponsored by University of Washington.

NCT05720819 is a NA study of Virtual Reality and Chronic Migraine that has completed, run by University of Washington. The registered enrollment target is 50 participants, below the 90-participant average among 19 other Virtual Reality trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05720819, a NA study of Virtual Reality and Chronic Migraine, has completed, sponsored by University of Washington.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Migraine is a common, debilitating neurologic condition affecting more than 900 million individuals worldwide. Established treatments for migraine include medications, vitamin and herbal supplements, neuromodulation, and behavioral treatment strategies. This study aims to determine whether a novel, home-based behavioral approach, combined biofeedback-virtual reality therapy, can improve self-reported migraine-related outcomes in individuals living with chronic migraine. In this randomized, controlled pilot study, 50 adults with chronic migraine are randomized to the experimental group (frequent use of a heart rate variability biofeedback-virtual reality device plus standard medical care; n=25) or wait-list control group (standard medical care alone; n=25). The primary outcome is reduction in mean monthly headache days between groups at 12 weeks. Secondary outcomes include mean change in acute analgesic use frequency, depression, migraine-related disability, stress, insomnia, and catastrophizing between groups at 12 weeks. Tertiary outcomes include change in heart rate variability and device-related user experience measures.

Primary Outcome

Mean headache days per month in the experimental group, as compared with mean headache days per month in the control group.

Interventions

  • DEVICE Combined biofeedback-virtual reality device

Study Locations (1)

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2020-09-09
Est. Completion 2022-03-01
Phase NA
University of Washington

1,048 total trials

What the finished NCT05720819 record still lists

NCT05720819 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 90-participant average among 19 other Virtual Reality trials with a reported enrollment target (44% lower).

The record links to 5 conditions, with Virtual Reality appearing as the primary indexed condition, and to 1 intervention - of which Combined biofeedback-virtual reality device is the first listed.

NCT05720819 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT05720819 about?

NCT05720819 is a clinical study titled "Biofeedback-VR for Treatment of Chronic Migraine". Migraine is a common, debilitating neurologic condition affecting more than 900 million individuals worldwide. Established treatments for migraine include medications, vitamin and herbal supplements, neuromodulation, and behavioral treatment strategies. This study aims to determine whether a novel, ...

What is the current status of trial NCT05720819?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2020-09-09. Estimated completion is 2022-03-01.

What conditions does trial NCT05720819 study?

This clinical trial studies the following conditions: Virtual Reality, Chronic Migraine, Biofeedback, Behavioral Treatment, Medication Overuse Headache.

What interventions are being tested in trial NCT05720819?

The interventions under investigation include: Combined biofeedback-virtual reality device (DEVICE).

Who is sponsoring clinical trial NCT05720819?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05720819 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Virtual Reality

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05720819's enrollment target sits among peer trials

50 9th of 19 higher than 11 of 19 other Virtual Reality trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Virtual Reality trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05720819, the US trial registry maintained by the National Library of Medicine. NCT05720819 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.